Latterell Venture Partners was formed in 2001 to invest exclusively in early stage healthcare companies, including biotechnology, pharmaceutical, research instrument, biomaterial, medical device, healthcare IT, and diagnostic ventures.
The differentiating feature of LVP is the unique blend of technical, clinical, operational, entrepreneurial and venture capital skills of our partners. Our team consists of two seasoned venture capitalists from Venrock and Sprout/Merrill Lynch, a leading clinician engineer from Stanford Medical School, a former senior research and development executive from Roche Pharmaceuticals and Centocor, a successful medical device entrepreneur and senior R&D executive from Boston Scientific, and a former biopharmaceutical entrepreneur and CEO from Molecular Biosystems. The partners work collaboratively with each other and with entrepreneurs drawing upon each other's strengths and spending significant time together to ensure the optimal success of each of our portfolio companies.
LVP has more than $300 million of committed capital to help our startup ventures achieve success.